Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2026)
Taysha Gene Therapies (TSHA) reported Other Non Operating Income of -$31000.0 for Q1 2026, down 338.46% on a YoY basis from $13000.0 in Q1 2025, and down 104.21% sequentially from $736000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 5 years of Other Non Operating Income data on file, last reported at -$31000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 338.46% year-over-year to -$31000.0; the trailing twelve-month figure through Mar 2026 stood at $941000.0 (up 563.55% YoY), and the FY2025 full-year result was $1.2 million, up 1190.0% from the prior year.
- Other Non Operating Income declined to -$31000.0 in Q1 2026, from $736000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $100.5 million in Q3 2023 to a low of -$177000.0 in Q4 2024.
- A 5-year average of $8.5 million and a median of $1000.0 in 2022 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income soared 10045700.0% in 2023 and sank 338.46% in 2026, its largest moves.
- Tracing TSHA's Other Non Operating Income over 5 years: stood at -$6000.0 in 2022, then surged by 579133.33% to $34.7 million in 2023, then tumbled by 100.51% to -$177000.0 in 2024, then jumped by 515.82% to $736000.0 in 2025, then plunged by 104.21% to -$31000.0 in 2026.
- Business Quant data shows TSHA's Other Non Operating Income at -$31000.0 in Q1 2026, $736000.0 in Q4 2025, and -$37000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31,000.00 |
| Dec 31, 2025 | 736,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | -177,000.00 |
| Sep 30, 2024 | -81,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Mar 31, 2024 | 337,000.00 |
| Dec 31, 2023 | 34.74 Mn |
| Sep 30, 2023 | 100.46 Mn |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | -8,000.00 |
| Dec 31, 2022 | -6,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -3,000.00 |